Healthcare

Jaguar Health Announces 1-for-25 Reverse Stock Split

Jaguar Health announced a 1-for-25 reverse stock split intended to support compliance with Nasdaq listing standards, with split-adjusted trading expected to begin on November 24, 2026.

Published:
Reading Time
2 min

Jaguar Health, Inc. (Nasdaq:JAGX) has announced plans for a 1-for-25 reverse stock split of its issued and outstanding voting common stock. The company said the action is intended to support compliance with Nasdaq's listing standards and follows approval by stockholders at its November 2026 Special Meeting of Stockholders.

#Reverse Stock Split Timing

The reverse stock split is scheduled to take effect at 12:01 am Eastern Time on Tuesday, November 24, 2026. Jaguar Health expects its common stock to begin trading on a split-adjusted basis when the market opens on that date.

The shares are expected to continue trading on The Nasdaq Capital Market under the symbol “JAGX.” The company has identified the expectation regarding split-adjusted trading as a forward-looking statement subject to risks, uncertainties and assumptions.

#How the Share Conversion Will Work

Under the announced ratio, every 25 shares held immediately before the Effective Date will be automatically reclassified as one share of common stock. The company said the par value per share will not change.

Jaguar Health will not issue fractional shares in the reverse stock split. Stockholders who would otherwise receive a fractional share will instead receive a cash payment in lieu of that share.

#Stockholder and Brokerage Details

Equiniti Trust Company, LLC is serving as the exchange agent. It will provide instructions to stockholders of record who hold paper stock certificates and need to exchange them for post-split shares.

Stockholders whose shares are held through brokerage accounts or in “street name” are not required to take action to complete the exchange, according to the company.

The new CUSIP number for Jaguar Health's common stock following the reverse stock split is 47010C839.

#Approval and Company Background

The reverse stock split follows approval of a proposal presented at Jaguar Health's November 2026 Special Meeting of Stockholders. Details of the proposal were included in the company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 8, 2026.

Jaguar Health develops proprietary prescription drugs derived from plants for people with complicated gastrointestinal disease states. Its family companies include Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., which focus on crofelemer powder for oral solution for rare and orphan gastrointestinal disorders involving intestinal failure. Magdalena Biosciences, a joint venture between Jaguar and Filament Health Corp., is focused on plant-derived prescription medicines for mental health indications.

#Key Takeaways

  • Jaguar Health announced a 1-for-25 reverse stock split of its voting common stock.
  • The split is scheduled to take effect at 12:01 am Eastern Time on Tuesday, November 24, 2026.
  • Split-adjusted trading is expected to begin at market open under the Nasdaq symbol “JAGX.”
  • No fractional shares will be issued; eligible holders will receive a cash payment in lieu of a fractional share.
  • The new CUSIP number will be 47010C839.

Original source: Read original article

Frequently Asked Questions